Advertisement

Topics

Lu AE58054

17:18 EST 22nd November 2017 | BioPortfolio

Lu AE58054 is a potent and selective 5-HT6-receptor antagonist. The 5-HT6-receptor is primarily found in areas of the brain involved in cognition. A number of early trials have demonstrated that a 5-HT6-receptor antagonist could offer potential benefits in the treatment of disorders such as Alzheimer's disease and in December 2009 Lundbeck initiated the above described 24 week clinical phase II trial with Lu AE58054 as augmentation therapy in Alzheimer's disease.

Quick Search
Advertisement
 

review and buy Lu AE58054 market research data and corporate reports here